September 21, 2021

Pfizer and BioNTech apply for COVID-19 vaccine emergency use in the US

An illustration picture shows vials with Covid-19 Vaccine stickers attached and syringes with the logo of US pharmaceutical company Pfizer and German partner BioNTech, on November 17, 2020. (Photo by JUSTIN TALLIS / AFP) (Photo by JUSTIN TALLIS/AFP via Getty Images)

Pfizer and Germany partner BioNtech have applied for Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA) for their COVID-19 vaccine candidate. The Pfizer vaccine has shown 95 percent efficiency against the deadly coronavirus. This is considered the first major step to aid the eradication of the deadly coronavirus. The application was made in a video posted on the official website of the company, Reuters quotes Pfizer Chief Executive officer. This is the first COVID-19 vaccine to seek regulatory clearance in the US. During the phase 3 trial, the vaccine was 95% effective with no major side effects. FDA panel will discuss emergency use of the vaccine on 10th Dec.

Leave a Reply

Your email address will not be published. Required fields are marked *